Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Annex Advisory Services LLC

Annex Advisory Services LLC boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 13.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 99,190 shares of the company's stock after buying an additional 12,045 shares during the quarter. Annex Advisory Services LLC owned approximately 0.33% of Medpace worth $30,222,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of MEDP. SBI Securities Co. Ltd. purchased a new position in Medpace in the fourth quarter valued at $31,000. Jones Financial Companies Lllp boosted its stake in Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after acquiring an additional 110 shares in the last quarter. Lindbrook Capital LLC boosted its stake in Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after acquiring an additional 29 shares in the last quarter. Assetmark Inc. boosted its stake in Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after acquiring an additional 29 shares in the last quarter. Finally, Colonial Trust Co SC boosted its stake in Medpace by 150.0% in the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock valued at $58,000 after acquiring an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Insider Buying and Selling at Medpace

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the transaction, the director now owns 2,998 shares in the company, valued at approximately $904,856.36. The trade was a 36.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 20.30% of the stock is owned by company insiders.

Medpace Price Performance

Medpace stock traded up $2.92 during mid-day trading on Friday, reaching $296.50. The company had a trading volume of 421,400 shares, compared to its average volume of 359,731. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $459.77. The company has a market capitalization of $8.52 billion, a P/E ratio of 23.48, a P/E/G ratio of 3.81 and a beta of 1.47. The stock's 50-day simple moving average is $298.07 and its 200-day simple moving average is $323.80.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The company had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. During the same period last year, the company posted $3.20 earnings per share. On average, equities analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MEDP has been the subject of several research analyst reports. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Mizuho decreased their target price on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. TD Cowen downgraded shares of Medpace from a "buy" rating to a "hold" rating and decreased their target price for the stock from $370.00 to $328.00 in a research note on Monday, April 14th. Leerink Partners assumed coverage on shares of Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 target price for the company. Finally, Robert W. Baird decreased their target price on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $349.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.